BML-260

• Description :

  BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  PPAR; STAT

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/bml-260.html

• Purity :

  99.65

• Solubility :

  DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(O)C1=CC=C(N(C/2=O)C(SC2=C\C3=CC=CC=C3)=S)C=C1

• Molecular Formula :

  C17H11NO3S2

• Molecular Weight :

  341.40

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Williams D R, et al. Targeting phosphatase DUSP22 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression[J]. bioRxiv, 2024: 2024.04. 08.588643.|[2]Feng Z, et al. Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression[J]. Theranostics, 2019, 9 (12) : 3501.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [101439-76-3]